PATS
PATS is an Indoor Drone Solutions enables greenhouse farmers to significantly reduce and eliminate flying insect pest populations
PATS is an Indoor Drone Solutions enables greenhouse farmers to significantly reduce and eliminate flying insect pest populations
PATS has raised $3.2M across 1 round. Its most recent round was a Seed of $3.2M in Sep 2025. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
PATS is featured in
Similar companies
Heritable Agriculture focuses on improving plant breeding and biotechnology to strengthen the world's food and agricultural systems.
Cellar Insights Provides potato growers with a simple way to remotely monitor and act on storage conditions.
Advanced Crop Science
African Golden Food is an agribusiness focused on producing cereal, grains, pulses, and vegetables.
Avisorex is a project designed to transform the agricultural sector through an integrated model of supply, distribution.
Fragaria is a high-tech farming company.
Area 2 Farms is an agricultural company that provides production and delivery services for organic vegetables and produce.
Interpose is an agriculture company providing fertilizer blends sustainability and profitability industries.
Growmark is an agricultural supply cooperative that provides agriculture-related products and services.
ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.
uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. Our first product, Glybera, was approved by the European Commission in October 2012 under exceptional circumstances for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD, a potentially life-threatening, orphan metabolic disease. We are also developing a pipeline of additional adeno-associated virus (AAV)-based gene therapies through multiple collaborations. We develop our gene therapies using our innovative, modular technology platform, including our proprietary manufacturing process. We initially are focused on orphan diseases but believe that we will also be able to develop gene therapies targeting chronic and degenerative diseases that affect larger populations.
Droppie is a recycling company that makes recycling easy and more accessible for consumers. The app is designed to help consumers recycle more effectively by offering small rewards for their recycled materials.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.